VIA
BPMC

Vident Investment Advisory’s Blueprint Medicines BPMC Stock Holding History

Vident Investment Advisory’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-7,077
Closed -$449K – 935
2018
Q2 		$449K Buy
7,077
+916
+15% +$72.9K 0.02% 692
2018
Q1 		$539K Buy
+6,161
New +$531K 0.02% 582

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Vident Investment Advisory's BPMC Position: Q3 2018 in Review

Vident Investment Advisory sold out of Blueprint Medicines (BPMC) in Q3 2018, closing a stake of 7,077 shares — an estimated $449K sold.

Vident Investment Advisory first reported a position in BPMC in Q1 2018 and held it in 2 quarters. The position peaked at $539K in Q1 2018. 188 funds tracked by Wall St. Rank hold BPMC as of Q3 2018.

  • Vident Investment Advisory reported no remaining Blueprint Medicines position as of Q3 2018 after selling out during the quarter.
  • Vident Investment Advisory sold 7,077 Blueprint Medicines shares in Q3 2018, an estimated $449K.
  • Vident Investment Advisory first reported a position in Blueprint Medicines in Q1 2018 and held it in 2 quarters.
  • Vident Investment Advisory's Blueprint Medicines position peaked at $539K in Q1 2018.
  • 188 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2018.

Based on Vident Investment Advisory's 13F filing for Q3 2018, filed 14 Nov 2018.